<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00422032</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0535</org_study_id>
    <nct_id>NCT00422032</nct_id>
  </id_info>
  <brief_title>2 Arm Study of Clofarabine IV in MDS Patients</brief_title>
  <official_title>Phase II Randomized Study of Two Different Schedules of Intravenous Clofarabine in Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the effectiveness of 2 different doses
      of the drug clofarabine that can be given on a weekly schedule for the treatment of
      Myelodysplastic Syndrome (MDS). The safety of these two doses will also be compared.

      Primary Objective: Compare the response rates of two dose schedules of clofarabine in MDS.

      Secondary Objective: Compare response durations, survivals and side effects of the two
      schedules.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clofarabine is a new chemotherapy drug that is designed to interfere with the growth and
      development of cancer cells.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of two treatment groups (Groups A and B). Participants in Group
      A will receive a lower dose of clofarabine. Participants in Group B will receive a higher
      dose of clofarabine. At first, there will be an equal chance of being assigned to either
      group. However, as experience increases and more information becomes available, the chance of
      being assigned to the group that has shown the most effectiveness will increase. You and the
      study doctor will know to which group you are assigned.

      Participants will receive clofarabine as a 1-hour infusion into a vein once a day for 5 days
      in a row. This will be repeated every 4 to 8 weeks. Each 4-8 week period is considered 1
      cycle of treatment.

      For participants in both groups, after each cycle of therapy, they will not receive the next
      cycle of chemotherapy until their blood counts have recovered and any possible side effects
      have gone away (for around 4 to 8 weeks). You must stay in Houston for the first treatment
      cycle (about 4 to 8 weeks) and will be required to return to Houston before receiving each
      additional cycle of chemotherapy (up to 6 days each cycle).

      Before every treatment cycle, your doctor will perform a physical exam, including measurement
      of your weight and vital signs (blood pressure, heart rate, temperature, and breathing rate).
      You will be asked about the level of your daily activities and how you are feeling. You will
      have blood samples (about 1-2 teaspoons) collected for routine lab tests 1-2 times a week for
      the first cycle, then every 2-4 weeks while on therapy. Repeat bone marrow samples will be
      collected every 1-3 cycles. However, if you complete the study before the third cycle, the
      bone marrow may be taken then. You may choose to have check-up visits and blood tests with
      your local doctor.

      If you show a response and do not experience any severe side effects, you can receive up to a
      total of 12 cycles of therapy. During each cycle, clofarabine will be given the same way as
      during the first cycle. However, the dose of clofarabine may be lowered during later cycles
      to decrease the risk of side effects that may have occurred in previous cycles. If the
      disease gets worse or you experience any intolerable side effects, you will be taken off the
      study and your doctor will discuss other treatment options with you.

      This is an investigational study. Clofarabine is approved by the FDA for treatment of
      pediatric acute lymphoblastic leukemia. Its use in this study is experimental. Up to 60
      participants will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response for Two Dose Schedules of Clofarabine</measure>
    <time_frame>4 weeks (minimum 1 cycle) up to 24 weeks (maximum 3 cycles of 8 weeks)</time_frame>
    <description>Response defined as Complete Remission (CR): Normalization of blood counts with neutrophils &gt;/= 1 * 10^9/L and platelet counts &gt;/= 100 * 10^9/L, and marrow blasts &lt;/=5%; Partial Remission: as above except for presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment; or Hematologic Improvement (HI): Complete Response (CR) with the exception of a lack of platelet recovery to &gt;/= 100 * 10^9/L. Repeat bone marrow samples collected every 1-3 cycles (4-8 week cycle).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>15 mg/m^2 Clofarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg/m^2 Clofarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>Group A: 15 mg/m^2 IV over 1 hour daily for 5 days
Group B: 30 mg/m^2 IV over 1 hour daily for 5 days</description>
    <arm_group_label>15 mg/m^2 Clofarabine</arm_group_label>
    <arm_group_label>30 mg/m^2 Clofarabine</arm_group_label>
    <other_name>Clolar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with MDS and &gt;/= 5% blasts or International Prognostic Scoring System (IPSS)
             risk intermediate or high; patients with Chronic Myelomonocytic Leukemia (CMML).

          2. No prior intensive chemotherapy or high-dose ara-C (&gt; 1g/m2).

          3. Prior biologic therapies, targeted therapies, or single agent chemotherapy allowed.

          4. Patients must have been off chemotherapy for 2 weeks prior to entering this study and
             recovered from the toxic effects of that therapy, unless there is evidence of rapidly
             progressive disease.

          5. Hydroxyurea is permitted for control of counts prior to treatment.

          6. Procrit, GCSF are allowed before therapy.

          7. Performance 0-2 (Eastern Cooperative Oncology Group (ECOG)). Adequate organ function
             including the following: Adequate liver function (bilirubin of &lt; 2mg/dl), and renal
             function (creatinine &lt; 2mg/dl), and SGPT (ALT) &lt; 3 * upper limit of normal (ULN).
             Adequate cardiac functions (New York Heart Association (NYHA) cardiac III-IV
             excluded).

          8. Signed informed consent.

        Exclusion Criteria:

          1. Nursing and pregnant females. Patients of childbearing potential should practice
             effective methods of contraception. Should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately.

          2. Active and uncontrolled infections.

          3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          4. Prior clofarabine treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop Kantarjian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdanderson.org</url>
    <description>M.D. Anderson's Website</description>
  </link>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>June 22, 2012</results_first_submitted>
  <results_first_submitted_qc>June 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 27, 2012</results_first_posted>
  <last_update_submitted>June 22, 2012</last_update_submitted>
  <last_update_submitted_qc>June 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Clofarabine</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period 1/31/06 - 9/21/09. All patients were registered at The University of Texas M.D. Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 60 participants registered on this study, two (2) were excluded prior to receiving treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>15 mg/m^2 Clofarabine</title>
          <description>Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days</description>
        </group>
        <group group_id="P2">
          <title>30 mg/m^2 Clofarabine</title>
          <description>Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>15 mg/m^2 Clofarabine</title>
          <description>Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days</description>
        </group>
        <group group_id="B2">
          <title>30 mg/m^2 Clofarabine</title>
          <description>Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="25" upper_limit="89"/>
                    <measurement group_id="B2" value="65" lower_limit="34" upper_limit="83"/>
                    <measurement group_id="B3" value="68" lower_limit="25" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response for Two Dose Schedules of Clofarabine</title>
        <description>Response defined as Complete Remission (CR): Normalization of blood counts with neutrophils &gt;/= 1 * 10^9/L and platelet counts &gt;/= 100 * 10^9/L, and marrow blasts &lt;/=5%; Partial Remission: as above except for presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment; or Hematologic Improvement (HI): Complete Response (CR) with the exception of a lack of platelet recovery to &gt;/= 100 * 10^9/L. Repeat bone marrow samples collected every 1-3 cycles (4-8 week cycle).</description>
        <time_frame>4 weeks (minimum 1 cycle) up to 24 weeks (maximum 3 cycles of 8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15 mg/m^2 Clofarabine</title>
            <description>Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days</description>
          </group>
          <group group_id="O2">
            <title>30 mg/m^2 Clofarabine</title>
            <description>Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response for Two Dose Schedules of Clofarabine</title>
          <description>Response defined as Complete Remission (CR): Normalization of blood counts with neutrophils &gt;/= 1 * 10^9/L and platelet counts &gt;/= 100 * 10^9/L, and marrow blasts &lt;/=5%; Partial Remission: as above except for presence of 6-15% marrow blasts, or 50% reduction if &lt;15% at start of treatment; or Hematologic Improvement (HI): Complete Response (CR) with the exception of a lack of platelet recovery to &gt;/= 100 * 10^9/L. Repeat bone marrow samples collected every 1-3 cycles (4-8 week cycle).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematologic Improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years, 10 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>15 mg/m^2 Clofarabine</title>
          <description>Lower Dose Clofarabine Group A: 15 mg/m^2 intravenous (IV) over 1 hour daily for 5 days</description>
        </group>
        <group group_id="E2">
          <title>30 mg/m^2 Clofarabine</title>
          <description>Higher Dose Clofarabine Group B: 30 mg/m^2 IV over 1 hour daily for 5 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Prolonged Myelosuppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="37"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia/bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Transaminase elevations</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="37"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="37"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hagop Kantarjian, MD / Professor</name_or_title>
      <organization>The University of Texas M. D. Anderson Cancer Center</organization>
      <phone>713-792-7026</phone>
      <email>eharriso@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

